Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Zoledronic acid for treament of prostate cancer

2009 ASCO Annual Meeting

29 May - 2 Jun 2009

Published: 25 Jun 2009

Views: 16395

Rating:

Save

Dr. Thomas W. Leonard, Chief Scientific Officer, Merrion Pharmaceuticals

Results of Phase II study comparing Orazol (zoledronic acid in oral form) to Zometa (zoledronic acid IV) injections in treatment of prostate cancer, as presented at the ASCO Meeting, 2009. Further comment from Chief Development Officer Dr John Fox.

Related Videos

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard

Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis

Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )

Autovaccination with the intratumoral viral mimic poly-ICLC makes a cold tumour hot in prostate cancer

Dr Sujit Nair - Icahn School of Medicine at Mount Sinai, New York, USA

Autovaccination with the intratumoral viral mimic poly-ICLC makes a cold tumour hot in prostate cancer ( Dr Sujit Nair - Icahn School of Medicine at Mount Sinai, New York, USA )

Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising efficacy mHSPC

Prof Bertrand Tombal - Université Catholique de Louvain, Brussels, Belgium

Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising efficacy mHSPC ( Prof Bertrand Tombal - Université Catholique de Louvain, Brussels, Belgium )

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective perioperative strategy for MIBC

Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective perioperative strategy for MIBC ( Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy )

More from ecancer